Novo Nordisk’s weight loss drug Wegovy received accelerated FDA approval for treating metabolic dysfunction-associated steatohepatitis (MASH), a prevalent liver condition. Phase 3 trials demonstrated Wegovy’s ability to improve liver scarring and resolve MASH without worsening fibrosis. This marks Wegovy as the first glucagon-like peptide-1 (GLP-1) receptor agonist approved for this indication, with potential to impact a market previously led by Madrigal Pharmaceuticals' Rezdiffra.